US FDA Warns Indoco To Delve Further Into Manufacturing Deviation

Data integrity and process control found lacking

On paper, the tablet press was in control. In reality, it was not. What did that mean for the company? A lot more than it appeared to realize.

Vintage inscription made by old typewriter, warning

A deviation investigation into a papered-over problem with a tablet press was so inadequate that the US Food and Drug Administration sent a warning letter about it to the company, Indoco Remedies Ltd., Mumbai, India.

The 16 July warning letter reflects two of FDA’s enforcement priorities: strong data integrity and thorough investigations.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Compliance

More from Pink Sheet